Posted on April 14, 2021 by Aaron Warwick
Today, Biotricity (BTCY), a medical diagnostic and consumer healthcare technology company, announced pre-audited numbers for their FY 2021. Their FY 2021 sales were 133% higher than in FY 2020. But even more impressive was their run rate exiting March 2021. To wit, the CEO stated their revenue for March 2021 was $580,000. This puts them on an annual run rate of over $7M for FY 2022. That alone would represent 100%+ revenue growth again in FY 2022, with likely more upside ahead as they have grown sales each month for two plus years. In addition, they have the possibility of adding a new product, pending FDA approval, later this year.
Disclosure: I am long BTCY and may buy/sell shares at any time.